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ABSTRACT
Dosimetry of 90Y Liquid Brachytherapy in a Dog with Osteosarcoma Using
PET/CT. (May 2011)
Jingjie Zhou, B.E., Tsinghua University
Co-Chairs of Advisory Committee: Dr. Gamal Akabani
Dr. John W. Poston, Sr.
A novel 90Y liquid brachytherapy strategy is currently being studied for the treat-
ment of osteosarcoma using a preclinical translational model in dogs to assess its
potential efficacy and toxicity. In this study, dosimetry calculations are performed
for 90Y liquid brachytherapy in a dog with osteosarcoma using the Geant4 Monte
Carlo code. A total of 611.83 MBq 90Y radiopharmaceutical is administered via
direct injections, and the in vivo distribution of 90Y is assessed using a time-of-
flight (TOF) PET/CT scanner. A patient-specific geometry is built using anatomical
data obtained from CT images. The material properties of tumor and surrounding
tissues are calculated based on a CT number - electron density calibration. The
90Y distribution is sampled in Geant4 from PET images using a collapsing 3-D re-
jection technique to determine the decay sites. Dose distributions in the tumor bed
and surrounding tissues are calculated demonstrating significant heterogeneity with
multiple hot spots at the injection sites. Dose volume histograms show about 33.9%
of bone and tumor and 70.2% of bone marrow and trabecular bone receive a total
dose over 200 Gy; about 3.2% of bone and tumor and 31.0% of bone marrow and
trabecular bone receive a total dose of over 1000 Gy. 90Y liquid brachytherapy has
the potential to be used as an adjuvant therapy or for palliation purposes. Future
work includes evaluation of pharmacokinetics of the 90Y radiopharmaceutical, cali-
bration of PET/CT scanners for the direct quantitative assessment of 90Y activity
concentration, and assessment of efficacy of the 90Y liquid brachytherapy strategy.
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NOMENCLATURE
1-D One-dimensional
2-D Two-dimensional
3-D Three-dimensional
ASCII American Standard Code for Information Interchange
CT Computed Tomography
DCE-MRI Dynamic Contrast-enhanced MRI
DICOM Digital Imaging and Communications in Medicine
DVH Dose Volume Histogram
18F−FDG 18F−Fluoro-2-deoxy-glucose
FOV Field of View
FWHM Full-width at Half Maximum
HU Hounsfield Unit
LET Linear Energy Transfer
MIP Maximum Intensity Projection
MRI Magnetic Resonance Imaging
mTOR Mammalian Target of Rapamycin
PET Positron Emission Tomography
SEER Surveillance, Epidemiology and End Results
SPECT Single Photon Emission Computed Tomography
SUV Standard Uptake Value
TOF Time-of-flight
TRT Targeted Radionuclide Therapy
VEGF Vascular Endothelial Growth Factor
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11. INTRODUCTION
Osteosarcoma is the most common primary malignant bone tumor, mainly affecting
children, adolescents and young adults. The radiographic features, histological char-
acteristics, clinical presentations and standard treatment of osteosarcoma have been
described in many book chapters and review articles [1,2]. However, there has been
little improvement in the survival and therapeutic strategies for osteosarcoma in the
last 20 years. This leads to the investigation of novel treatment approaches and
multi-modality strategies. This chapter reviews the general aspects of osteosarcoma,
including epidemiology, histopathology, conventional treatment options, emerging
therapies and preclinical animal studies.
1.1 Epidemiology of Osteoesarcoma
1.1.1 Incidence
The incidence rate of cancer increases with age. According to the analysis of
the Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review
of the National Cancer Institute 1975-2007, the overall incidence rate of cancer for
all ages is 462.6 per 100,000 in the United States based on data from 2003 to 2007.
For ages from 0 to 19, the incident rate of cancer is 16.7 per 100,000 during the same
time period. The incidence rate of cancer for all ages has experienced an increase
from 400.39 per 100,000 in 1975 to a peak as 510.73 per 100,000 in 1992 and then
dropped to 472.68 per 100,000 in 2007. The incidence rate for ages from 0 to 19
shares the trend, exhibiting an increase in occurrence of childhood and adolescents
cancer since 1970s [3]. The incident rate of cancer is higher in male than in female
This thesis follows the style of Nuclear Medicine and Biology.
2for all cancer sites combined. Similarly, childhood and adolescents cancer affect boys
more frequently than girls.
For all bone and joint cancers, the incidence rate is 0.9 per 100,000 for all ages,
accounting for 0.19% of total cancer incidence for all ages but 5.39% for ages from
0-19. Among all malignant bone tumors for all ages, osteosarcoma is the most
common type accounting for 35% of all cases, followed by chondrosarcoma (25%)
and Ewing’s sarcoma (16%), respectively. In children and adolescents, osteosarcoma
represents about 56% of bone cancers and Ewing’s sarcoma represents about 34% [2].
A primary peak in osteosarcoma incidence occurs in children and adolescents at ages
0-24, corresponding to the peak period of skeletal growth. A plateau of incidence
is observed at ages 25-59, and there is a secondary peak of osteosarcoma incidence
in the elderly (60-85+). The incidence rates of osteosarcoma is 0.44 per 100,000 for
ages 0-24 and is 0.42 per 100,000 for ages 60-85+ [4]. The incidence of osteosarcoma
has always been considered to be higher in males than in females, with a rate of 5.4
per million persons per year in males vs. 4.0 per million in females [2].
Osteosarcoma can occurs in any bone. However, the portions of skeleton with
highest growth rate are most frequently affected. Osteosarcoma often occurs near the
metaphyseal growth plates of the long bones of the extremities. The most common
sites are the femur (42%), the tibia (19%), and the humerus (10%). Other likely
locations are the skull or jaw, the vertebra, and the pelvis [2, 5].
1.1.2 Mortality and Survival
According to SEER Cancer Statistics Review 1975-2007, the mortality rate of all
bone and joint cancers for all ages is 0.4 per 100,000, with a 5-year overall survival
rate of 68.2%. For children at ages 0-14, the mortality rate is 0.1 per 100,000, and
for children and adolescents at ages 0-19, the mortality rate is 0.2 per 100,000 [3].
Bone and joint tumor is the third cause of death in children, followed by leukemia
and brain tumors [2].
3The National Cancer Institute SEER Study for the years 1975-1995, reported that
the overall 5-year survival rate for patients with osteosarcoma diagnosed between
1974 and 1994 was 63%. In another recent report based on data from 1973-2004, the
relative 5-year survival rate was 61.6% for patients with ages 0-24, 58.7% for ages
25-59, and 24.2% for ages 60-85+ [4]. The strategy of using adjuvant chemotherapy
with surgery has greatly improved the survival rate of osteosarcoma in the past
decades. Survival increased significantly between 1973-83 and 1983-93, but there
is little change subsequently [4]. Therefore, new treatment strategies need to be
developed.
1.2 Histopathology
Osteosarcoma develops from propagation of malignant mesenchymal tumor cells
which have the ability to produce osteoid extracellular matrix or immature bone.
Conventional osteosarcoma can be divided into three categories according to the
predominant matrix product of the tumor cells: 1) osteoblastic, 2) chondroblastic,
and 3) fibroblastic. A mixture of production pattern is usual and small biopsies may
not represent the overall histology of a tumor [1].
Generally, the tumor is a combination of bony and soft tissues showing significant
heterogeneity, with areas varying in color, consistency, and degree of ossification. Os-
teosarcoma exhibits an invasive and bone-destroying pattern of growth. The borders
between the tumor tissue and adjacent structures are indistinct and irregular. The
small lesions are usually eccentrically located within the medullary cavity. The ad-
vanced lesions tend to invade the cortex, fill the medullary, progress toward the shaft
and growth plate, and expand into soft tissue. Interactions between tumor osteoid
and preexisting non-tumor bone produce large, densely ossified areas which may
merges with adjacent cortex. Further growth of tumor produces an ball-like mass
that overlies the large cortical defect and compresses surrounding muscles. Signs of
periosteal reaction can often be seen at the periphery of the tumor lesion [1].
41.3 Imaging Assessment
Conventional radiography is usually used in the initial evaluation of the bone
lesions. The radiographic presentation of osteosarcoma is usually a combination
of osteolytic and sclerotic lesions with gradual transition to normal bones, which
makes the borders of the lesions hard to define. The mineralization of tumor matrix
exhibits cloudy opacities, which can be either uniformly distributed or clustered
in one area. As previously described, the cortex is often involved and destroyed,
resulting indistinct outer limits of the cortex in the area of penetration. As the
tumor extends to soft tissue, its mineralization shadow can be seen overlying the
area of penetration [1].
Magnetic resonance imaging (MRI) is employed in local staging because of its su-
perb capabilities to evaluate the extent of intramedullary involvement and extension
into soft tissue. Dynamic contrast-enhanced MRI (DCE-MRI) is used to evaluate
the status of tumor angiogenesis for treatment planning [2].
Detailed examination of the lungs and bones is required to determine the presence
of clinically detectable metastases. Computed tomography (CT) can be used as aid
for conventional radiography in diagnosis of osteosarcoma in tubular and complex
bones, but its primary role is to detect pulmonary metastases.
18F− FDG PET is often performed for the whole body to detect metastatic
spread and local recurrence. 18F-fluoro-2-deoxy-glucose is the most commonly used
positron emission tracer in PET oncology. After administration, 18F− FDG accumu-
lates in locations with high glucose metabolism. Since tumors are hypermetabolic,
the standard uptake value (SUV) of 18F− FDG can be a sensitive indicator of ma-
lignancy [6]. Questions concerning the appropriate SUV cut-off value persist, but
generally those lesions with an SUV greater than 2.0 are malignant (aggressive), and
those below 2.0 are benign [7]. 18F− FDG PET scans can also be used to assist in
tumor staging and guide biopsy to the most biologically active region [2].
51.4 Metastasis and Recurrence
Osteosarcoma metastasizes through hematogenous spread [8]. At diagnosis, 80%
of the cases are localized osteosarcoma while 20% of the patients are found with
metastasis. Lungs are the most common metastatic sites, followed by other bones [9].
A retrospective study was carried out in Italy by Bacci et al. regarding 1,148 patients
in 27 years period. 0.4% of patients who relapsed had local recurrence, 12% had local
recurrence plus metastases, and 88% had metastases only [10]. The relapse rate for
patients with inadequate surgical margins was significantly higher than those with
adequate surgical margins. The first site of metastases was the lung with 89% of
cases, 8% of patients had metastases in other bones and only 2% had metastases in
other organs. The average time to relapse was 21.3 months [10].
1.5 Current Treatment Options
1.5.1 Surgery
Generally, surgery for osteosarcoma is a wide excision which removes the en-
tire tumor and a cuff of adjacent normal tissue [11]. A more radical excision can
be an amputation or disarticulation. Historically, most patients were treated with
amputation. Limb-salvage surgery is now an alternative option, which spares more
normal tissue and enables better reconstruction outcomes. The choice of surgery type
depends on location and extent of disease and response of primary tumor to preoper-
ative chemotherapy. For patients with metastases, especially pulmonary metastases,
surgery to remove all sites of disease must be considered. Reconstruction of the limb
is performed after surgery. Common options of reconstruction include osteoarticular
allograft, prosthesis, or a combination of the two [11].
61.5.2 Chemotherapy
Advances in chemotherapy over the past 30 years have improved limb salvage
outcome and led to higher survival rates. Surgery with adjuvant modern multi-
drug chemotherapy has dramatically increased the 5-year disease-free survival rate
of patients to 60-70% [9]. Chemotherapy has also been shown to reduce or delay
the onset of pulmonary metastases. Agents commonly used in chemotherapy for
osteosarcoma includes methotrexate (MTX), cisplatin, doxorubicin, and ifosfamide
(IFO) [9].
For patients with non-metastatic osteosarcoma, current standard strategy is pre-
operative chemotherapy before surgery plus postoperative chemotherapy after surgery.
Preoperative chemotherapy induces necrosis in the primary tumor which facilitates
surgical resection and provides early treatment of micrometastatic diseases [12]. The
postoperative chemotherapy or maintenance chemotherapy is carried out after the
surgery. The postoperative chemotherapy should be chosen based on the degree
of tumor necrosis induced by preoperative chemotherapy. The role of chemother-
apy dose intensity in osteosarcoma has been widely debated. However, no relation
between dose intensity and prognosis has been established so far [9].
For patients already diagnosed with metastases (synchronous metastatic osteosar-
coma), the same chemotherapy strategy is used, but the prognosis of patients is poor.
For patients with relapse, there is no standardized treatment so far. Resection of
all metastatic sites is preferred, while the role of chemotherapy after relapse is still
under debate. For patients not eligible for metastasectomy, chemotherapy is used for
palliation purposes [9].
Recent improvements in chemotherapy have been achieved based on the under-
standing of the mechanism of resistance to agents in osteosarcoma cells. For ex-
ample, the chemotherapy agent trimetrexate has been used in combination of high
dose methotrexate in clinical trials. The rationale of this strategy is that trimetrex-
ate works on transport-defective cells while methotrexate works on transport-normal
7cells. The non-overlapping toxicities of the two agents allow administrations at max-
imum dose intensity [11].
1.5.3 External Radiation Therapy
It is rare to use radiotherapy as a primary treatment for osteosarcoma. However,
radiotherapy is an important option for patients with unresectable tumors and for
palliation purposes. The most common modality of radiotherapy for osteosarcoma
is external photon therapy, while experiences with proton, neutron and heavy ions
radiotherapy for osteosarcoma have been very limited. An analysis was performed
by Schwarz et al. based on patient data from the Cooperative Osteosarkomstudi-
engruppe (COSS)-Registry, which included 100 patients treated with radiotherapy
for osteosarcoma [13]. A total of 94 patients received external photon therapy; 2
patients, proton therapy; 2 patients, neutron therapy; and 2 patients, intraoperative
radiotherapy. The median dose for external RT was 55.8 Gy (ranging from 30 Gy
to 120 Gy). The local control rates were calculated with a median follow-up of 1.5
years. Local control rates for combined surgery and radiotherapy were significantly
better than those for radiotherapy alone, which demonstrates the benefit of combined
treatment modalities.
1.5.4 Targeted Radionuclide Therapy
Targeted radionuclide therapy (TRT) uses unsealed radiolabeled compounds to
deliver therapeutic doses of ionizing radiation to tumor sites [14]. Such radiopharma-
ceutical formulations may be solutions or colloidal suspensions and the administra-
tion can be either systemic or locoreginal. Radiopharmaceuticals used for TRT are
designed to target widely disseminated lesions, such as secondary tumors or metas-
tases [14]. Targeted radionuclide therapy has been used for the treatment of cancers
for several decades, and current technological advances in molecular biology and bio-
8chemistry have enabled the production of radiopharmaceuticals with sophisticated
molecular carriers with enhanced capability of targeting tumor cells [15].
Primary issues in the design of TRT agents include selection of radionuclides, ef-
ficiency of drug delivery, residence time of radioactivity at target sites and clearance
time in normal tissues, and in vivo catabolism and metabolism of the drug. The
choice of a radionuclides depends on its physical half-life, decay scheme, radiative
properties, pharmacokinetics of the radiopharmaceutical, cost, and availability [15].
Radionuclides used in radiopharmaceutical therapy include β-particle emitters such
as 90Y and 188Re, α-particle emitters such as 211At, and Auger electron emitters,
such as 125I. Radionuclides with β-particle emissions are the most commonly used in
radiopharmaceutical therapy. β-particles have a continuous energy spectrum ranging
from zero to a maximum value. These electrons have relatively longer ranges com-
pared to α-particles, so they are able to produce a spread out dose distribution in
the tumor. On the other hand, α-particles have short ranges of a few cell diameters,
so the dose deposition is highly localized, thus sparing surrounding normal tissues.
With a relatively high LET about 100 keV/µm, α-particles also produce more direct
damage to the tumor cells. Auger electrons deposit energy within the diameter of a
cell. Therefore, the auger electron emitting radiopharmaceuticals need to be bound
to the DNA in the tumor cell nucleus for efficient cell killing. However, the design of
effective Auger-emitting targeting agents remains a great challenge [15].
A number of radiopharmaceuticals have been used in the treatment of human
bone metastatic disease, including 32P-sodium orthophosphate, 89Sr − chloride and
153Sm-EDTMP which have been approved by the FDA for rountine use in humans,
186Re − HEDP which has been approved in Europe, and 188Re − HEDP which has
been undergoing clinical trials but not yet approved by the FDA. The administration
of radiopharmaceuticals can be driven by site-directed molecular carriers or depend
on specificity in organ uptake, such as iodide uptake in thyroid cells. For bone
cancers, the accumulation of radioactivity in sites of growing and remodeling bone is
9determined by the chemical properties of the so-called ”bone seekers” radionuclides.
32P-sodium orthophosphate and 89Sr − chloride are the first two agents used in the
treatment of painful bone metastases, while the former is rarely used today. 153Sm-
EDTMP, 186Re−HEDP and 188Re−HEDP are newly introduced bone seeker agents
which have been intensively studied in clinical trials. Even though the biophysical
properties and pharmacokinetic profiles of these agents vary from each other, they
have comparable efficacy in pain relief and similar acceptable hematological toxicity
[16].
153Sm-EDTMP has been used in the treatment of osteosarcoma as an addition
to external beam therapy or chemotherapy, giving an extra dose to the tumor, while
the benefit of the strategy is still under investigation [17]. In the analysis of COSS-
Registry data by Schwarz et al., 100 patients with osteosarcoma were treated with
external radiation therapy and 17 of them received an extra dose of 153Sm-EDTMP.
Local control for patients given an addition of 153Sm-EDTMP was worse than those
who received external radiation therapy alone, though not statistically significant.
The survival rate for patients with additionally administered 153Sm-EDTMPF was
not significantly different in comparison to that of other patients [13].
1.6 Emerging Therapies
1.6.1 Biological Target Therapies
Biological targeted therapy aims at blocking genes and signal transduction path-
ways responsible for the malignant behavior in osteosarcoma. A number of signal
transduction pathways and receptors have been intensively studied as potential tar-
gets for the treatment of osteosarcoma, such as mTOR pathway, IGF-1 receptor,
HER2/neu and VEGF receptor.
mTOR (mammalian target of rapamycin) pathway mediates cell growth and
differentiation [11]. mTOR inhibitors have been shown to be effective against os-
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teosarcoma cells in preclinical studies [9]. IGF-1 (insulin-like growth factor-1) is a
major regulator of normal cell growth. It has been demonstrated that several key
signal transduction pathways downstream of the IGF-1 receptor are activated in os-
teosarcoma cell lines. Several agents targeting on IGF-1 receptor are being tested in
Phase I and II clinical trials [11]. HER2/neu is a member of the epidermal growth
factor receptor family. The over expression of HER2/neu has been identified in
a variety of carcinomas, including breast, ovarian, endometrial, prostate and lung.
However, the prognostic significance of HER2/neu in osteosarcoma remains contro-
versial. A Phase II clinical trial using the monoclonal antibody tratuzumab that
targets the HER2/neu receptor, as an addition to standard chemotherapy in pa-
tients with HER2/neu expressing osteosarcoma is being conducted by the Children’s
Oncology Group [18]. The vascular endothelial growth factor (VEGF) is a naturally
occurring protein that stimulates the development of tumor-associated blood vessels
necessary for the tumor growth and metastases [9]. Inhibitors of the VEGF recep-
tor are being studied for their efficacy of preventing tumor angiogenesis in various
cancers, including osteosarcoma [11].
Therapies that focus on the tumor interaction with its microenvironments are
also studied. For example, bisphosphonates have been studied with in in vitro os-
teosarcoma models, showing the capacity to inhibit tumor growth and to disrupt
the tumor interactions with its surrounding microenvironment [11]. The adjuvant
benefit of bisphosphonates administrated as an addition to chemotherapy has also
been demonstrated both in vitro and in vivo. However, further clinical investigations
are needed to assess the anti-tumor efficacy of bisphosphonates in human osteosar-
coma [19].
1.6.2 α-particle Emitting 223Ra Radionuclide Therapy
The α-particle emitting 223Ra is a promising agent for targeted radionuclide ther-
apy for bone cancer and bone metastases and it has been widely tested in clinical
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trials. The radionuclide 223Ra produces a cascade of α-particles from decaying daugh-
ter radionuclides with a suitable half-life (11.34 d). The half-lives of its daughters are
relatively short compared to other α-particle emitting radium radioisotopes, elimi-
nating the translocalization problem of daughter products [20].
Preclinical studies have shown that cationic 223Ra is an avid bone-seeker with
high uptake in metabolically active osteoblastic bone and tumor lesions and little
uptake in soft tissue. The daughter radionuclides can be well retained with minimal
translocalization [20]. 223RaCl2 has been used in clinical trials for the treatment of
skeletal metastases from breast and prostate cancers, resulting in impressive anti-
tumor activity and improved overall survival [20]. Liposome-encapsulated 223Ra has
also been evaluated for the treatment of osteosarcoma [20]. The biodistribution and
tumor uptake of 223Ra was assessed in preclinical studies using mice with human
osteosarcoma xenografts and dogs with spontaneous osteosarcoma and associated
soft tissue metastases. Considerably higher uptake of 223Ra was observed in dogs in
both calcified and non-calcified tumor metastases in different organs than in normal
soft tissues [20].
1.6.3 90Y Liquid Brachytherapy
The radionuclide 90Y is a β-particle emitter that decays to stable daughter 90Zr
with a half-life of 64.2 hours and an average energy of 0.934 MeV. The maximum
range of 90Y β-particles in water is 1.1 cm. 90Y is available in a convenient generator
system and is able to be incorporated into many compounds, including complexes,
chelates and monoclonal antibodies [21]. 90Y labeled therapeutic microspheres have
been approved for the routine use in human to treat primary and metastatic hepatic
cancers. As one of the many bone seeker radioisotopes, 90Y has also been considered
for the treatment of bone cancers and metastases. A few attempts have been made
to evaluate the pharmacokinetics of 90Y labeled radiopharmaceutical. In vivo studies
in mice showed desirable high uptake in bone and fast clearance in soft tissues and
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other organs, suggesting the feasibility of using 90Y for the treatment of bone cancer
and metastases [22,23].
A novel 90Y liquid brachytherapy agent is currently being studied for the treat-
ment of osteosarcoma. Liquid brachytherapy is a new technique recently introduced
to the field of radiopharmaceutical therapy [24]. Therapeutic radioisotopes are ad-
ministrated via direct injections to tumor sites to minimize the activity loss and
consequent hematological toxicity. In the case of osteosarcoma, since 90Y is a bone
seeker, we expect a high retention of radioactivity in the osteoblastic tumors and
metastases and low uptake in soft tissues. As mentioned before, radiotherapy has
been always an alternative for patients with unresectable tumors and for palliation
purpose. For the disseminated tumor which is difficult to treat with external beam
therapy, 90Y agent should be able to deliver a localized high dose to the tumor and
spare the surrounding normal tissue, considering the range of 90Y β-particles.
Another advantage of 90Y liquid brachytherapy is that the biodistribution of 90Y
can now be assessed non-invasively using a PET scanner. The decay of 90Y contains a
minor branch to the 0+ first excited state of 90Zr, followed by a transition of internal
pair production [25]. The maximum energy of positrons was determined to be 800
keV. The branching ratio of positron emission was measured as (31.8±0.47)×10−6 by
Selwyn et al. [26]. Modern PET scanners using time-of-flight (TOF) reconstruction
are able to assess the biodistribution of 90Y radiopharmaceutical with good image
quality. Lhommel et al. showed that TOF PET image of 90Y better reflected the
tumor heterogeneity assessed by FDG PET/CT than traditional bremsstrahlung
90Y-SPECT [27]. PET imaging allows for the dosimetry of 90Y liquid brachytherapy
in the tumor and surrounding tissues.
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1.7 Preclinical Studies Using Dogs with Osteosarcoma
1.7.1 Similarities Between Dog and Human Osteosarcoma
Animals have been widely used in the studies of a variety of diseases, including
cancer, for a better understanding of the similar processes in humans. Spontaneously
developing osteosarcoma in dogs is an excellent translational model for osteosarcoma
in humans due to the similarities they share in many aspects, including male sex
predilection, affected sites, pathology and treatment response.
Osteosarcoma in dogs is much common than in humans. Prevalence estimates
suggest that over 8000 new cases occur each year in United States. Most affected
dogs are large or giant purebreds. 90% of canine osteosarcoma patients are greater
than 20 kg. The peak age of incidence of osteosarcoma in dogs is seven years. The
incidence rate of osteosarcoma in dogs is higher in male than that in female, which is
same as the situation in humans. For both humans and dogs, the most common site
of osteosarcoma is the metaphyseal growth plates in long bones of the limbs. The
majority of human tumors occurs in legs, while most of the canine cases occur in the
front legs [28].
The most common metastatic site for both species is lungs, followed by other
bones. Osteosarcoma in humans and dogs have similar histopathological features.
Both species have a mixed matrix production pattern in the tumor and significant
variation for the type and size of involved cells. More important, informative com-
parison of human and canine osteosarcoma demonstrated a strong similarity of the
genomic expression pattern of the two [29].
Treatment options for dogs with osteosarcoma includes surgery, chemotherapy
and radiotherapy. The response to treatment in dogs is also similar to that of hu-
mans. Both exhibits improved survival rate with adjuvant chemotherapy and high
metastases rate with surgery or radiotherapy alone.
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1.7.2 Translation of Therapies from Dog to Human
Preclinical studies in dogs have played an important role in the development of
new cancer treatment strategies over the past decades. Compared to tumor mouse
models, spontaneous dog models are more similar to human tumor in its growth
time period, genomic expression, heterogeneity in tumor cells and tumor microen-
vironment [30]. Therefore, preclinical studies in dogs with osteosarcoma can assist
in assessing the safety and efficacy of treatment strategies and predicting their re-
sponse in human patients. As an example, dogs with osteosarcoma were used to
assess the preoperative and postoperative treatment to optimize limb-sparing surgi-
cal procedures, which is currently used in the management of osteosarcoma in human
patients [30].
Preclinical studies of 90Y liquid brachytherapy are being performed using dogs
with osteosarcoma. The results from these studies are expected to contribute to
our understanding of the safety and efficacy of the 90Y radiopharmaceutical. In this
study, we performed three-dimensional (3D) dosimetry calculations of 90Y liquid
brachytherapy in dogs with osteosarcoma to assess its dose distribution in the tumor
bed and surrounding tissues.
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2. MATERIAL AND METHODS
2.1 90Y Liquid Brachytherapy Preclinical Protocol
2.1.1 Diagnostic 18F-FDG PET/CT Scan
A diagnostic 18F-FDG PET/CT scan is performed to detect the distribution
of tumor using a Siemens Biograph mCT. The scanner is equipped with 128 slice
molecular CT and high resolution TOF PET with extended field-of-view (FOV).
An example of the co-registered 18F-FDG PET/CT 3-D maximum-intensity-
projection (MIP) is shown in Figure 2.1. The tumor exhibits a group of heterogenous
hot lesions with irregular borders. The average SUV in the volume of interest is 6.00
with a maximum of 36.23, suggesting a very high activity of glucose metabolism in
the tumor.
Fig. 2.1. 18F-FDG PET/CT co-registered 3-D MIP view showing
the tumor in a dog with osteosarcoma.
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Figure 2.2 is a 3-D rendering image of 18F-FDG PET/CT for a dog with osteosar-
coma, which clearly shows the cortex has been penetrated and destroyed. The 3-D
rendering view helps physicians to delineate the target treatment area on the dog’s
skin and predefine the locations of injection sites.
Fig. 2.2. 18F-FDG PET/CT co-registered 3-D view showing the
tumor in a dog with osteosarcoma.
2.1.2 Preparation of Injection Sites
The 90Y radiopharmaceutical is administrated at multiple injection sites to cover
as much as possible the total tumor volume. The injection sites are distributed
uniformly in the delimitated treatment area, spaced approximately 1 cm from each
other. After an injection site is chosen, a needle-like adaptor is inserted to touch
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the bone. The adaptor consists of three parts: a) an outer cannula, b) an inner
cannula, and c) a cap. A specially designed miniature electric drill is used to drill
on the osteoid tumor bed through the adapter to allow the direct injection of the
radiopharmaceutical, as shown in Figure 2.3.
Fig. 2.3. Preparation of injection sites for 90Y liquid brachytherapy
in a dog with osteosarcoma. Before the administration of the ra-
diopharmaceutical, adaptors are inserted at multiple injection sites
distributed around the delimitated treatment area. A specially de-
signed miniature electric drill is used to drill on the osteoid tumor
bed through a adaptor.
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After drilling, the adaptor is left in situ to stop blood from filling up the orifice
and the cap is inserted to isolate the wound from air-borne contaminants.
After all the adaptors are inserted, a radiograph is taken to examine the placement
and integrity of the adaptors to make sure the tumor volume is completely covered,
as shown in Figure 2.4.
Fig. 2.4. Adaptor placement radiograph before injection of the
90Y liquid brachytherapy in a dog with osteosarcoma.
2.1.3 90Y Radiopharmaceutical Injection
The 90Y radiopharmaceutical formulation is prepared as solution with an activity
concentration about 100 µCi/µl (3.7 × 104Bq/µl). The solution is usually dyed in
blue so that it can be easily visualized in the syringe. A micro-needle syringe is used
to perform the injection. For each adaptor, about 15 µl of 90Y radiopharmaceutical
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is injected at 3 or 4 spots at different depths, spaced about 1 cm from each other.
The adaptor is removed after the injection.
The volume of 90Y solution in the syringe before and after each injection is
recorded to determine the total volume injected. A picture of the 90Y injection
is shown in Figure 2.5.
Fig. 2.5. The injection of 90Y solution for 90Y liquid brachytherapy
in a dog with osteosarcoma. 90Y solution was injected using a micro-
needle syringe through a cannula.
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2.1.4 90Y PET/CT Scan
A 90Y PET/CT scan is performed with a Siemens Biograph mCT PET/CT scan-
ner after the injection is finished to assess the in vivo activity distribution of 90Y.
The 90Y PET scan usually lasts 1 hour. The PET image reconstruction method is
ultraHD which uses TOF information.
2.2 The Conversion of CT Number to Material Properties
2.2.1 CT number - Electron Density Calibration
In this study, CT images in DICOM format are used to build a patient specific
geometry for the Monte Carlo simulations. Anatomic information in the CT im-
ages is characterized by CT numbers (Hounsfield Unit, HU). However, mass density
and elemental composition are required to define a material in most Monte Carlo
codes. Thus, a method to convert CT numbers into material properties needs to be
developed. The Hounsfield unit H assigned to a voxel is given by the equation:
H = (
µ
µH2O
− 1)1000, (2.1)
where µ is the total attenuation coefficient of the tissue in that voxel averaged over
the energy spectrum of the CT x-ray. It is assumed that the total attenuation has
been corrected for the beam hardening effect, i.e. the energy spectrum is location
independent. For a compound or mixture, the total attenuation is given by:
µ = ρNA
n∑
i=1
(
ωi
Ai
σi), (2.2)
where ρ is mass density of the material, NA is the Avogadro constant, ωi is the
elemental weight of element i, Ai is the mass number of element i, and σi is the
photon interaction cross section of element i averaged over the x-ray energy spectrum.
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Because Compton effect is the predominant interaction process for photons at CT
x-ray energies (from 50 keV to 200 keV), σi can be approximated as below [31]:
σi ≈ σincoh = ZiσKN , (2.3)
where σincoh is the average cross section of incoherent scattering (Compton scatter-
ing), Zi is the atomic number of element i , σKN is the average Klein-Nishina cross
section, which is a constant for a particular energy spectrum. Thus,
µ ≈ σKNρNA
n∑
i=1
(
ωi
Ai
Zi). (2.4)
Note that ρNA
∑n
i=1(
ωi
Ai
Zi) is the electron density of the material. Although
equation 2.4 is a rough approximation, it is natural to relate CT number to electron
density of the material.
Parker et al. suggested a linear relationship between CT number and electron
density of human tissues with a flex point around HU = 65 [32]. Similar results
were found by other authors [33–36]. Differences between authors were observed,
especially in high CT numbers corresponding to bone materials, due to differences
in scanners and tissue equivalent materials used for the calibrations. Therefore it is
recommended that each CT scanner should be calibrated with an electron density
phantom to accurately measure the relationship between CT number and electron
density.
In this study, a CIRS (Computerized Imaging Reference Systems, Inc.) 062
electron density phantom is used for the CT number - electron density calibration.
The phantom consists of a two-part body made of soft tissue equivalent epoxy resin,
holding eight pairs of tissue equivalent inserts, and a solid water insert with known
electron densities, as shown in Figure 2.6. For each pair of tissue equivalent inserts,
one of the inserts is placed in the inner plate while the other in the outer ring. The
solid water insert is placed in the center of the phantom.
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Fig. 2.6. CIRS 062 electron density phantom used for the CT num-
ber - electron density calibration. The phantom contains a two-part
body, eight pairs of tissue equivalent inserts and a solid water insert.
Tissue equivalent inserts include lung (exhale and inhale), adipose
tissue, breast, liver, muscle, trabecular bone and dense bone.
The phantom is scanned using the Siemens Biograph PET/CT scanner. For
each insert, the average CT number is determined by drawing a circular ROI with
a diameter of approximately 2 cm on a central slice CT image. The CT number
for each tissue equivalent material is the average of the inner plate and outer ring
measurements. A calibration curve is obtained by plotting the average CT number
against relative electron density (electron density normalized to that of water). Once
the calibration is established, the relative electron density of each voxel in patient
CT images can be calculated using linear interpolation.
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2.2.2 Material Grouping and Density Bins
The relevant materials in this study are listed in Table 2.1. The material density,
electron density, and elemental composition data for all the materials are taken from
ICRU 46 [37].
Table 2.1
Material Groups for the Monte Carlo Simulations of 90Y Liquid
Brachytherapy in a Dog with Osteosarcoma based on ICRU 46
Group Material Density Relative Electron Relative Electron
g/cm3 Densitya Density Range
Air Air 1.20× 10−3 1.08× 10−3 [0, 0.1)
Soft Soft Tissue 1.00 0.991
[0.1, 1)
Tissue Yellow Marrow 0.98 0.982
Red Marrow 1.03 1.02
[1.0, 1.1)
Red Muscle 1.05 1.04
Marrow Blood 1.06 1.05
Cartilage 1.10 1.08
Bone Trabecular Bone 1.16 1.14
[1.1, +∞)
and Tumor Cortical Bone b 1.92 1.78
a The electron density of the material over that of water.
b The elemental composition of this group is determined by interpolation of cortical bone and
blood.
The materials are divided into four groups according to their relative electron
density: Air, Soft Tissue, Red Marrow, and Bone and Tumor. Voxels in the CT
images can be sorted into these groups according to the relative electron density ρwe
calculated from CT numbers. The materials with their names in bold are specified
as the reference materials. The elemental composition of voxels in each group is
determined by the reference material of the group, except for those in the Bone and
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Tumor group. Bone and Tumor group includes trabecular bone, tumor, and cortical
bone, with the density of material varying in a wide range. Trabecular bone is a
mixture of dense bone, bone marrow and blood; and the tumor of osteosarcoma, as
mentioned before, is usually a combination of bony and soft tissue, with its electron
density in the range of the Bone and Tumor group. Therefore, the material in
the Bone and Tumor group is defined as a mixture of cortical bone (high density
component) and blood (low density component) to better simulate the nature of the
material in this group.
For voxels in Air, Soft Tissue, and Red Marrow groups, the elemental compo-
sition is fixed within each group while the mass density changes with a step size
corresponding to 0.1 of relative electron density. For each bin, the relative electron
density at the mid-point is used. The mass density ρ of the voxel is then calculated
using equation 2.5:
ρ =
ρwe
ρwe,ref
ρref (2.5)
where ρwe is the relative electron density of the voxel, ρ
w
e,ref is the relative electron
density of the reference material in that group and ρref is the mass density of the
reference material.
For voxels in the Bone and Tumor group, the elemental composition and mass
density both change with step sizes corresponding to 0.1 of relative electron density.
For each bin, the relative electron density at the mid-point is used. If ρwe ≤ ρwe,c,
where ρwe is the relative electron density of the voxel and ρ
w
e,c is the relative electron
density of cortical bone, the fractions of cortical bone and blood for each voxel are
calculated by interpolation, as shown in equation 2.6:
{ fcρ
w
e,c + fbρ
w
e,b = ρ
w
e
fc + fb = 1
(2.6)
where ρwe,b is the relative electron density of blood, fc is the fraction of cortical bone
and fb is the fraction of blood. If ρ
w
e > ρ
w
e,c, the fraction of cortical bone is assumed
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to be 1 and the fraction of blood is 0. The elemental composition of the voxel can
be expressed as equation 2.7:
ωi = fcωc,i + fbωb,i (2.7)
where ωi is the elemental weight of element i for that voxel, ωc,i is the elemental
weight of element i for cortical bone and ωb,i is the elemental weight of element i for
blood. Then the mass density is calculated using equation 2.8:
ρ = fc
ρwe
ρwe,c
ρc + fb
ρwe
ρwe,b
ρb (2.8)
where ρc is the mass density of cortical bone and ρb is the mass density of blood.
The electron mass stopping power of the materials in the Soft Tissue and Red
Marrow groups were calculated using the web-based program ESTAR [38], as shown
in Figure 2.7. The total mass stopping power for all the materials are similar, with
standard deviations less than 2%. The mass electron stopping power are barely
affected by elemental composition. Therefore, it is proper to use the elemental com-
position of the reference material for the whole group.
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Fig. 2.7. Comparison of total mass stopping power of human tissue
for electrons with energy ranging from 0 to 3 MeV.
2.3 PET Image Sampling
The activity distribution of 90Y is sampled using PET images to determine the
decay sites for Monte Carlo simulations. PET images in DICOM format are read as
a 3-D array. A collapsing 3-D rejection technique is used to improve the efficiency of
sampling [39]. To determine the indices (i, j, k) for one decay, the activity distribution
array is firstly collapsed over the z-axis to sample k. Secondly, after k is chosen, the
two-dimensional array on the corresponding plane k is collapsed over the y-axis to
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sample j. Finally, i is sampled from the column j at plane k. Then the decay site
is randomized in the selected voxel. The coordinates (x, y, z) of the decay site are
calculated from the indices (i, j, k) using the following equation:
x = (i+ rx)∆x + origx,
y = (j + ry)∆y + origy,
z = (k + rz)∆z + origz,
(2.9)
where ∆x, ∆y, and ∆z are the voxel sizes along x, y, z axis respectively, rx, ry, and rz
are random numbers between -0.5 and 0.5 (assume the position of primary particle
is random in the voxel), and (origx, origy, origz) is the coordinates of the voxel with
indices (0, 0, 0).
2.4 Geant4 Monte Carlo Simulation
Techniques described in 2.2 and 2.3 are implemented in the Monte Carlo code
Geant4 for dosimetry calculations. Geant4 is a general purpose toolkit to simulate the
passage of particles through matter which has been widely used in nuclear physics,
accelerator design, space science and medical physics [40]. Geant4 includes a large
variety of functionalities with high degree of flexibility. It also contains complete
interaction cross section data files and physics processes over a wide energy range
from eV to TeV.
In these simulations, a patient-specific geometry is built using anatomical data ob-
tained from CT images. The material properties of tumor and surrounding tissues are
calculated based on a CT number - electron density calibration. The 90Y distribution
is sampled from PET images using a collapsing 3-D rejection technique to determine
the decay sites. The β− spectrum of 90Y is obtained from JANIS [41]. Then the
energy deposition in each voxel is calculated. Dosimetry results are given as spe-
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cific absorbed dose (S-values) in each voxel, with a unit of Gy/Bq-s. The following
equation is used to convert S-value, S to absorbed dose, D :
D = S[Gy/Bq− s]× A[Bq]× τ [s], (2.10)
where A is the total administrated activity, and τ is the residence time of 90Y radiopha-
rmaceutical. The residence time τ is given by the equation below:
τ =
1
λp + λb
(2.11)
where λp is the physical radioactive decay constant of
90Y and λb is the biological
clearance constant of the 90Y radiopharmaceutical. Since the pharmacokinetics of
the 90Y radiopharmaceutical hasn’t been assessed, τ is assumed to be the inverse of
λp. τ equals 3.32× 105 s.
2.5 3-D CT Segmentation
To evaluate the dose delivered to the bone, tumor and bone marrow separately,
3-D CT image segmentations are performed morphologically using a segmentation
software ITK-SNAP [42]. A segmentation can be generated either manually by
drawing regions of interest on the CT images, or automatically by specifying an CT
number window and a smoothness filter for the structure of interest. The segmenta-
tion result is saved as a 3-D binary array. The dose volume histogram (DVH) of a
structure of interest can be acquired by applying the segmentation array as a mask
with the dose distribution array.
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3. RESULTS AND DISCUSSION
3.1 CT Number - Electron Density Calibration
The CIRS 062 electron density phantom was scanned using the Siemens Biograph
mCT. The average CT number for each tissue equivalent insert and its standard
deviation were measured from the central slices of the reconstructed DICOM files
and plotted against the relative electron density, as shown in Figure 3.1. The average
standard deviation was 31.35 HU for all the materials. CT numbers from patient
images were converted to relative electron densities by linear interpolation of data
points and further converted into material properties as previous described.
Fig. 3.1. CT numbers with standard deviation against relative elec-
tron density for all tissue equivalent inserts. Material groups are
showed with corresponding relative electron density range.
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3.2 Preclinical Results
A 5 years old male dog with osteosarcoma in left tibia was treated with 90Y liquid
brachytherapy. The activity concentration of 90Y radiopharmaceutical solution was
78 µCi/µl (2.88 MBq/µl) and a total activity of 16.536 mCi (611.83 MBq) was
administrated. After administration, a 60 min PET/CT scan was performed to
assess the distribution of 90Y radiopharmaceutical. The collected PET data were
reconstructed using ultraHD (including TOF) with 3 iterations, 21 subsets and a
post-smoothing filter of 5 mm. A 3-D co-registered 90Y PET/CT image is shown in
Figure 3.2
Fig. 3.2. A 3-D co-registered PET/CT image showing the distri-
bution of 90Y in a dog treated with 90Y liquid brachytherapy for os-
teosarcoma. A high activity hot spot was found in the bone marrow
and multiple isolated hotspots in the tumor bed, corresponding to
the sites of administration.
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3.3 Geant4 Monte Carlo Simulation
3.3.1 Geometry
The reconstructed PET DICOM images had 200 × 200 pixels in 100 slices (203.6
mm × 203.6 mm × 300 mm). The pixel size was 1.018 mm × 1.018 mm and the slice
thickness was 3 mm. The reconstructed CT DICOM images were cropped to 209 ×
209 pixels in 100 slices (204.0 mm × 204.0 mm × 300 mm) with a pixel size of 0.976
mm × 0.976 mm and a slice thickness of 3 mm. A voxelized cubic phantom was
build in Geant4 geometry based on the cropped CT images. The phantom consisted
of a box with 209 × 209 × 100 voxels. The voxel size was 0.976 mm × 0.976 mm ×
3 mm. The material properties of each voxel were obtained from the CT number as
previously described in section 2.2.
A basic description of the Geant4 code developed for 90Y liquid brachytherapy
dosimetry is given in Appendix A. Selected lines from class files for DICOM image
handling and geometry setup are given in Appendix A.
3.3.2 Physics
In the Geant4 Monte Carlo simulations, the position of each primary particle
was determined by sampling the 90Y distribution from PET images, as described in
2.3. The momentum direction of primary particles was assumed to be isotropic. The
energy of each primary particle was determined by sampling the β-particle energy
spectrum of 90Y obtained from JANIS, as plotted in Figure 3.3. The average energy
per decay was 0.934 MeV and the maximum energy was 2.275 MeV. The cut value
of Monte Carlo transport for all particles was set as 0.01 mm, i.e. particles with a
range smaller than 0.01 mm would not be tracked and were assumed to deposit all
the remaining energy locally. The codes for primary particle generation and PET
image sampling are shown in Appendix A.
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Fig. 3.3. 90Y β-particle emission energy spectrum calculated by
JANIS. The average energy was 0.934 MeV and the maximum energy
was 2.275 MeV.
3.3.3 Dosimetry Calculations
The Geant4 Monte Carlo simulation was performed in 10 runs to assess the
uncertainties of all calculations with a total number of 108 particles transported.
The S-value in each voxel was recorded in binary files with unit in Gy/Bq-S . The
absorbed dose was calculated using equation 2.10.
The output files were handled using MATLAB (MATLAB 7.7.0, The MathWorks
Inc., Natick, MA, 2008.) The relevant commands are listed in Appendix B.
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3.4 90Y Liquid Brachytherapy Dosimetry
3.4.1 3-D Dose Distribution and Isodose Curves
A 3-D volume rendering of CT images fused with the dose distribution is shown
in Figure 3.4. The resulting dose distribution consisted of multiple hot-spots corre-
sponding to the injection sites.
Fig. 3.4. 3-D volume rendering of CT fused with dose distribution
of 90Y liquid brachytherapy in a dog with osteosarcoma in tibia.
Isodose curves were plotted on an axial plane, as shown in Figure 3.5. The
osteolytic lesions were covered in a total dose over 200 Gy with a central hot-spot of
over 1200 Gy. However, the bone marrow was also irradiated with a hotspot of over
1000 Gy.
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Fig. 3.5. Isodose curves on an axial plane, showing the dose distri-
bution in the tumor bed, adjacent bone and bone marrow.
3.4.2 Dose Volume Histograms
Two 3-D CT segmentations were generated to evaluate the dose delivered to the
tumor and surrounding tissues: 1) bone and tumor, and 2) bone marrow (including
trabecular bone). Because the tumor of osteosarcoma was mainly bony tissue with
intensity close to that of bone, it was difficult to separate tumor from adjacent
bone. The dose delivered to the tumor and bone was evaluated as an entity with
segmentation 1). Segmentation 1) was generated with a lower CT number threshold
of 400 HU and a smoothness filter of 2 mm. segmentation 2) was generated by
manually selecting the low density volume in the bone, including the red marrow,
trabecular bone, and yellow marrow in the medullary cavity. The two segmentations
are shown in Figure 3.6.
35
Fig. 3.6. 3-D CT segmentations in the (a) axial, (b) sagittal and (c)
coronal planes. Segmentation 1) bone + tumor is marked in red and
2) bone marrow (including trabecular bone) is marked in green.
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The CT number histograms for these two segmentations are shown in Figure 3.7.
Corresponding material groups are marked in the figure. Segmentation 1) as bone
and tumor is in the range of Muscle and Bone and Tumor group. Segmentation 2) as
bone marrow (including trabecular bone) is in the range of Soft Tissue and Muscle
group.
Fig. 3.7. CT number histograms for segmentation 1) as bone and
tumor, and 2) as bone marrow (including trabecular bone).
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(a) Normalized dose volume histograms for bone and tumor
and bone marrow (including trabecular bone).
(b) Co-registered 90Y PET/CT image showing a hot spot in
the medullary cavity, resulting high dose to the bone marrow
and trabecular bone.
Fig. 3.8. Normalized dose volume histograms for bone and tumor
and bone marrow (including trabecular bone), and corresponding
90Y activity distribution in a co-registered PET/CT image.
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Normalized dose volume histograms were calculated by applying the segmentation
masks to the 3-D dose distribution and shown in Figure 3.8(a). Relevant MATLAB
commands are given in Appendix B. The dose distribution in the tumor and other
tissues was extremely heterogenous. From the DVH data, about 33.9% of bone and
tumor and 70.2% of bone marrow and trabecular bone received a total dose over 200
Gy; about 3.2% of bone and tumor and 31.0% of bone marrow and trabecular bone
received a total dose of over 1000 Gy. The 90Y hot spot in the center of the bone as
shown in Figure 3.8(b) explained the high dose to the bone marrow and trabecular
bone. The uncertainties in absorbed dose to bone and tumor in each voxel were also
calculated. The average percentage standard deviation among all voxel was 13.4%,
with a range from 0% to 250%.
3.5 Discussions
3.5.1 Safety Concerns
During the injection of 90Y radiopharmaceutical, a small fraction of activity en-
tered the blood stream directly, causing hematological toxicity. Because 90Y is a
bone seeker, this activity loss resulted in a dose to the bone surfaces. This activity
loss should evaluated for safety concerns, which requires quantitative assessment of
90Y activity concentration from PET images. PET scanners should be calibrated
with 90Y in future to measure the 90Y activity concentration directly.
3.5.2 Limitations in the Current Dosimetry Calculations
There are two major limitations in the current dosimetry calculations. Firstly,
the activity loss during the injection should be excluded from the total administrated
activity. The improvement depends on the quantitative assessment of 90Y activity
concentration from PET images. Secondly, the pharmacokinetics of the radiophar-
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maceutical should be investigated in animals and the residence time τ should be
calculated with both physical radioactive decay and biological decay, as in equation
2.11. Then the absorbed dose should be re-calculated. Notice that the clearance rates
of 90Y radiopharmaceutical in the bone and tumor and in the soft tissue could be
different. Current dosimetry calculations were performed based on 90Y distribution
from PET/CT scan immediately after the injection. In the future, the changes in
90Y activity distribution with time should be considered for accurate dosimetry.
3.5.3 Dose Distribution of 90Y Liquid Brachytherapy
The heterogenous dose distribution of 90Y liquid brachytherapy mainly resulted
from the injection pattern: for each adaptor, the 90Y radiopharmaceutical was in-
jected at 3 or 4 spots spaced about 1 cm from each other. An alternative was to
administrated the radiopharmaceutical as a continuous line along the drilling hole
for a more uniform dose distribution. However, since the injection was performed
manually, it was extremely difficult to achieve.
Problems related with heterogenous dose distribution include inadequate dose
in tumor and high dose in normal tissues. In the 90Y liquid brachytherapy for os-
teosarcoma, the tumor usually merges with the adjacent cortex with a indistinct and
irregular border, it is difficult to separate the tumor from adjacent bone and estimate
the dose delivered to the normal bone.
In the meanwhile, it is also hard to evaluate the dose received by the red marrow
in the treated bone. Low density volume in the bone represents a mixture of red
marrow, trabecular bone, and yellow marrow in the medullary cavity. It is difficult
to separate these tissue from each other. The dose to the red marrow should be
carefully estimated according to the bone type and the tumor location in the bone.
In this study, all segmentations were performed using CT images morphologically.
MRI with supreme tissue differentiation ability should be considered as an alternative
for the definition of target treatment volume and segmentations.
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3.5.4 Efficacy and Potential Utility
The evaluation of the efficacy of 90Y liquid brachytherapy cannot be established
without acquiring large amount of preclinical data, including longitudinal data for in-
dividual dogs. Similar to 153Sm-EDTMP targeted radionuclide therapy, it is not likely
to use 90Y liquid brachytherapy as an primary treatment method for osteosarcoma.
The potential utility of 90Y liquid brachytherapy include being used as an addition
to chemotherapy or adjuvant therapy after surgery, being used for the treatment of
unresectable tumors or metastases, and for the pain palliation purposes.
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4. CONCLUSION
A novel 90Y liquid brachytherapy radiopharmaceutical is currently being studied
for the treatment of osteosarcoma using a preclinical translational model in dogs
to assess its potential efficacy and toxicity. In this study, dosimetry calculations
were carried out for the 90Y liquid brachytherapy in a dog with osteosarcoma using
Geant4. A patient-specific geometry was build using anatomy data obtained from
CT images. The material properties of tumor and surrounding tissues were obtained
from CT numbers based on an electron density phantom calibration. The in vivo
distribution of 90Y radiopharmaceutical was assessed using TOF PET scan, and then
sampled in Geant4 for Monte Carlo simulations.
The 3-D dose distribution of 90Y liquid brachytherapy showed significant hetero-
geneity with multiple hot spots corresponding to the injection sites. Dose volume
histograms were calculated for 1) bone and tumor, and 2) bone marrow (including
trabecular bone). From the DVH data, about 33.9% of bone and tumor and 70.2%
of bone marrow and trabecular bone received a total dose over 200 Gy; about 3.2%
of bone and tumor and 31.0% of bone marrow and trabecular bone received a total
dose of over 1000 Gy. The average percentage standard deviation of the absorbed
dose to bone and tumor was 13.4%, with a range from 0% to 250%.
90Y liquid brachytherapy has the potential to be used as an adjuvant therapy
or for palliation purposes. As for future work, dosimetry calculations should be
performed for more cases, and comparison should be made for osteosarcoma at dif-
ferent sites, with varied tumor volume, treated with different activity concentra-
tion and total activity. PET scanners should be calibrated to establish the direct
quantitative assessment of 90Y activity concentration. The pharmacokinetics of the
90Y radiopharmaceutical should also be studied. These studies allow the assessment
of hematological toxicity of 90Y liquid brachytherapy and accurate dosimetry calcu-
lations. Furthermore, the efficacy of the 90Y liquid brachytherapy alone or combined
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with other modalities in dogs with osteosarcoma should be evaluated with adequate
preclinical data.
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APPENDIX A
GEANT4 PET/CT APPLICATION
A.1. Introduction
The Geant4 application used for the 90Y liquid brachytherapy dosimetry (named
PETCT ) was developed from the DICOM application, which is one of the extended
example in Geant4.9.3.p01 package, under the directory \examples\extended\medical
\DICOM. The original DICOM example serves first to convert a CT DICOM file to
a simple ASCII file (.g4dcm file), where the CT numbers are converted to material
composition and densities to create a Geant4 geometry.
The PET/CT application performs the following major functios:
• PET DICOM file handling (implemented in PETHandler.cc): read a PET DI-
COM image sequence is read as a 3-D array and store the array in memory;
collapse the array along z-axis direction to a 1-D array, collapse each slice in the
3-D array along y-axis direction, and the collapsed results are stored in memory;
read the image position and sizes from the headers.
• CT DICOM file handling (implemented in CTHandler.cc): crop CT DICOM
images to match the PET image size; convert CT DICOM files to .g4dcm files,
which contain the material ID and relative electron density of converted from
the CT number of each voxel.
• Geometry construction (implemented in PETCTDetectorConstruction.cc): build
a voxelized cubic phantom was build in Geant4 geometry using information in
.g4dcm files.
• Sampling PET images (implemented in PETCTPrimaryGeneratorAction.cc):
sample the collapsed PET image arrays to determine the position of each pri-
mary particle.
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• Dosimetry calculation (implemented in PETCTRunAction.cc): score the dose
deposition in each voxel; write the scoring results of each run to a binary file,
where the unit of dose is Gy/Bq-s.
Supporting files of PET/CT application include:
• CT.dat, containing the total number and filenames of CT DICOM files.
• PET.dat, containing the total number and filenames of PET DICOM files.
• CT2REDensity.dat, containing the calibration data points to convert CT num-
ber to relative electron density.
• run.mac, containing the definition of primary particle energy spectrum.
Selected lines from PET/CT application class files are shown in A and A.
A.2. DICOM Image Handling and Geometry Setup
From PETHandler.cc:
...
void PETHandler :: CheckFileFormat ()
{
// Check existence of PET.dat
//if not exists , exit.
std:: ifstream checkData("PET.dat");
char * oneLine = new char[FILENAMESIZE ];
if(!( checkData.is\_open())) {
G4cout << "PET.dat does not exist!";
exit (0);
}
//Read dicom file names from PET.dat
// read the number of PET dicom files
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checkData >> nFiles;
checkData.getline(oneLine ,100);
char * name= new char[FILENAMESIZE ];
FILE * dicom;
for(int rep = 0; rep < nFiles; rep++) // begin loop on
filenames
{
checkData.getline(oneLine ,100);
std:: sprintf(name ,"%s.dcm",oneLine); //get the
filename of a dicom
std:: printf(" Opening %s and reading :\n",name);
dicom = std::fopen(name ,"rb"); //open a dicom
if( dicom != 0 )
{ ReadFile(dicom ,rep); } //read the dicom
else
{ G4cout << "\nError opening file : " << name <<
G4endl ;}
std:: fclose(dicom); // close the dicom
}
checkData.close (); //close "PET.dat"
// Normalized PETsum
for(int aa=0;aa <nFiles;aa++)
{PETsum[aa]= PETsum[aa]/ maxPETsum ;}
delete [] name;
delete [] oneLine;
}
//Read PET dicom files and store the image in arrays
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void PETHandler :: ReadFile(FILE *dicom ,int rep)
{
char * buffer = new char[LINEBUFFSIZE ];
implicitEndian = false;
littleEndian = true;
std:: fread( buffer , 1, 128, dicom ); // The first 128
bytes are not important
// Reads the "DICOM" letters
std:: fread( buffer , 1, 4, dicom );
if(std:: strncmp("DICM", buffer , 4) != 0) { //if there is
no "DICM" letters
std:: fseek(dicom , 0, SEEK_SET); //go back to
the beginning of the file
implicitEndian = true;
}
short readGroupId; // identify the kind of input data
short readElementId; // identify a particular type
information
short elementLength2; // deal with element length in 2
bytes
G4int elementLength4; // deal with element length in 4
bytes
char * data = new char[DATABUFFSIZE ];
// Read the header
//Get information with tags
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//If find the beginning of pixel data , break the loop
while(true) {
// Reading groups and elements :
readGroupId = 0;
readElementId = 0;
// group ID
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , readGroupId);
// element ID
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , readElementId);
// Creating a tag to be identified afterward
G4int tagDictionary = readGroupId *0 x10000 +
readElementId;
// VR or element length
std:: fread(buffer ,2,1,dicom);
GetValue(buffer , elementLength2);
// If value representation (VR) is OB , OW , SQ , UN , OF
or UT , the next length is 32 bits
if(( elementLength2 == 0x424f || // "OB"
elementLength2 == 0x574f || // "OW"
elementLength2 == 0x464f || // "OF"
elementLength2 == 0x5455 || // "UT"
elementLength2 == 0x5153 || // "SQ"
elementLength2 == 0x4e55) && // "UN"
!implicitEndian ) { // explicit VR
51
std:: fread(buffer , 2, 1, dicom); // Skip 2
reserved bytes
// element length
std:: fread(buffer , 4, 1, dicom);
GetValue(buffer , elementLength4);
// If find the beginning of the pixels , then break
if(tagDictionary == 0x7FE00010) break;
if(elementLength4 == 0xFFFFFFFF) G4cerr << "Too 
difficult for me!" << G4endl; // VR = SQ with
undefined length
// Reading data which follows the tag
std:: fread(data , elementLength4 ,1,dicom);
} else {
if(! implicitEndian || readGroupId == 2) { //
explicit with VR different than previous
ones
// element length (2 bytes)
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , elementLength2);
elementLength4 = elementLength2;
if(tagDictionary == 0x7FE00010) break; //
beginning of the pixels
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std:: fread(data , elementLength4 , 1, dicom);
} else { //
Implicit VR
// element length (4 bytes)
if(std:: fseek(dicom , -2, SEEK_CUR) != 0) {
G4cerr << "[PETHandler] fseek failed" <<
G4endl;
exit (-10);}
std:: fread(buffer , 4, 1, dicom);
GetValue(buffer , elementLength4);
if(elementLength4 == 0xFFFFFFFF) {// VR = SQ
with undefined length
short momreadGroupId;
short momreadElementId;
unsigned int momelementLength4 ; // deal
with element length in 4 bytes
while(true){
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , momreadGroupId);
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , momreadElementId);
std:: fread(buffer , 4, 1, dicom);
GetValue(buffer , momelementLength4);
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if(momelementLength4 == 0x00000000 ||
momelementLength4 == 0xFFFFFFFF )
break;
std:: fread(buffer , momelementLength4 , 1, dicom);
}
} else {
if(tagDictionary == 0x7FE00010) break; //
beginning of the pixels
std:: fread(data , elementLength4 , 1, dicom);
}
}
}
// Add a NULL termination
data[elementLength4] = ’\0’;
// analyzing data of each tag
GetInformation(tagDictionary , data);
}//end of the while loop
// --- Store Image Position :coordinates of the upper left
hand corner (first pixel) of the image
origX.push_back(ImagePositionX);
origY.push_back(ImagePositionY);
origZ.push_back(ImagePositionZ);
G4double sum=0; //sum of all pixels
G4double maxY =0; // maximum pixel value in a row
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if(bitAllocated == 8) {
// Case of 8 bits :
char ch;
for(G4int j = 0; j < rows; j++) {
for(G4int i = 0; i < columns; i++) {
sumY[rep][j]=0;
std:: fread(&ch , 1, 1, dicom);
image[rep][j][i] = ch;//store pixel values in
image
sumY[rep][j] += ch;//sum up in one row
sum += image[rep][j][i] ;//sum up the whole
slice
}
if(sumY[rep][j]>=maxY){maxY=sumY[rep][j];} //Get the
maximum of sumY
}
} else {
// case from 12 to 16 bits :
// Set the maxPixelValue to 0
maxPixelValue =0;
char sbuff [2];
short pixel;
for( G4int j = 0; j < rows; j++) {
sumY[rep][j]=0;
for( G4int i = 0; i < columns; i++) {
std:: fread(sbuff , 2, 1, dicom);
GetValue(sbuff , pixel);
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//Get the maxPixelValue in this slice
if(pixel >maxPixelValue)
{maxPixelValue=pixel ;}
image[rep][j][i] = pixel;//store pixel values
in image
sumY[rep][j]+= pixel;////sum up in one row
sum += image[rep][j][i] ;//sum up the whole
slice
}
if(sumY[rep][j]>=maxY){maxY=sumY[rep][j];} //
Get the maximum of sumY
}
}
// Normalize sumY
for(G4int yy=0;yy < rows;yy++)
{
sumY[rep][yy]=sumY[rep][yy]/maxY;
}
// Normalize the slice
for(int j=0;j<rows;j++)
{
for(int i=0;i<columns;i++)
{image[rep][j][i]= image[rep][j][i]/ G4double(
maxPixelValue);}
}
// Store the sum of this slice in the vector PETsum
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PETsum.push_back(sum);
if(sum >= maxPETsum)//Get the maximun of the sums of
slices
{maxPETsum=sum;}
delete [] buffer;
delete [] data;
}
void PETHandler :: GetInformation(G4int & tagDictionary , char *
data) {
if(tagDictionary == 0x00280010 ) { // Number of Rows
GetValue(data , rows);
std:: printf("[0 x00280010] Rows -> %i\n",rows);
} else if(tagDictionary == 0x00280011 ) { // Number of
columns
GetValue(data , columns);
std:: printf("[0 x00280011] Columns -> %i\n",columns);
} else if(tagDictionary == 0x00280100 ) { // Bits
allocated: This is how much computer memory will be
used to store a pixel sample.
GetValue(data , bitAllocated);
std:: printf("[0 x00280100] Bits allocated -> %i\n",
bitAllocated);
} else if(tagDictionary == 0x00280107 ) { // Max. pixel
value
GetValue(data , maxPixelValue);
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std:: printf("[0 x00280107] Max. pixel value -> %i\n",
maxPixelValue);
} else if(tagDictionary == 0x00080006 ) { // Modality
std:: printf("[0 x00080006] Modality -> %s\n", data);
} else if(tagDictionary == 0x00280030 ) { // Pixel Spacing
G4String datas(data);
int iss = datas.find(’\\’);
pixelSpacingX = atof( datas.substr(0,iss).c_str () );
pixelSpacingY = atof(datas.substr(iss+1,datas.length
()).c_str ());
} else if(tagDictionary == 0x00200032 ) { // Image
Position
G4String datas(data);
int iss = datas.find(’\\’);
ImagePositionX=atof( datas.substr(0,iss).c_str() );
G4String datas2=datas.substr(iss+1,datas.length ()).
c_str ();
iss = datas2.find(’\\’);
ImagePositionY = atof( datas2.substr(0,iss).c_str() );
ImagePositionZ=atof(datas2.substr(iss+1,datas.length ()
).c_str ());
std:: printf("[0 x00200032] Image Position (Patient ,mm) 
-> %s\n", data);
} else if(tagDictionary == 0x00180050 ) { // Slice
Thickness
sliceThickness = atof(data);
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std:: printf("[0 x00180050] Slice Thickness (mm) -> %f\n
", sliceThickness);
} else if(tagDictionary == 0x00020010) { // Endian
if(strcmp(data , "1.2.840.10008.1.2") == 0)
implicitEndian = true;
else if(strncmp(data , "1.2.840.10008.1.2.2", 19) == 0)
littleEndian = false;
}
}
...
From CTHandler.cc:
...
void CTHandler :: CheckFileFormat ()
{
petImagePositionX=PETHandler ::origX [0];
petImagePositionY=PETHandler ::origY [0];
petrows=PETHandler ::rows;
petcolumns=PETHandler :: columns;
petpixelSpacingX=PETHandler :: pixelSpacingX;
petpixelSpacingY=PETHandler :: pixelSpacingY;
// Check existance of CT.dat
std:: ifstream checkData("CT.dat");
char * oneLine = new char [128];
if(!( checkData.is_open ())) {
G4cout << "CT.dat does not exist!"<<G4endl;
exit (0);
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}
//Read the number of CT dicom files
checkData >> nFiles;
G4String oneName;
checkData.getline(oneLine ,100);
std:: ifstream testExistence;
G4bool existAlready = true;
for(G4int rep = 0; rep < nFiles; rep++) {
checkData.getline(oneLine ,100);
oneName = oneLine;
oneName += ".g4dcm"; // .g4dcm file name
// G4cout << "Check the existence of " << oneName <<
G4endl;
testExistence.open(oneName.data());
if(!( testExistence.is_open ())) {
existAlready = false;
testExistence.clear ();
testExistence.close ();
}
testExistence.clear();
testExistence.close();
}
ReadMaterialIndices( checkData );
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checkData.close ();
delete [] oneLine;
if( existAlready == false ) {
//g4dcm files don’t exist
// The files *. g4dcm have to be created
G4cout << "Creating g4dcm files"<<G4endl;
FILE * dicom;
FILE * lecturePref;
char * maxc = new char[LINEBUFFSIZE ];
char * name = new char[FILENAMESIZE ];
char * inputFile = new char[FILENAMESIZE ];
lecturePref = std::fopen("CT.dat","r");
std:: fscanf(lecturePref ,"%s",maxc);
nFiles = atoi(maxc);
G4cout << " Number of CT Files " << nFiles << G4endl;
for( G4int i = 1; i <= nFiles; i++ ) { // Begin loop
on filenames
std:: fscanf(lecturePref ,"%s",inputFile);
std:: sprintf(name ,"%s.dcm",inputFile);
// Open input file and give it to gestion_dicom :
std:: printf("### Opening %s ",name);
61
dicom = std::fopen(name ,"rb");
// Reading the .dcm file
if( dicom != 0 ) {
ReadFile(dicom ,inputFile);
} else {
G4cout << "\nError opening file : " << name <<
G4endl;
}
std:: fclose(dicom);
}
std:: fclose(lecturePref);
delete [] maxc;
delete [] name;
delete [] inputFile;
}
}
G4int CTHandler :: ReadFile(FILE *dicom , char * filename2)
{
G4cout << " ReadFile " << filename2 << G4endl;
G4int returnvalue = 0;
char * buffer = new char[LINEBUFFSIZE ];
implicitEndian = false;
littleEndian = true;
std:: fread( buffer , 1, 128, dicom ); // The first 128
bytes are not important
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// Reads the "DICOM" letters
std:: fread( buffer , 1, 4, dicom );
// if there is no preamble , the FILE pointer is rewinded.
if(std:: strncmp("DICM", buffer , 4) != 0) {
std:: fseek(dicom , 0, SEEK_SET);
implicitEndian = true;
}
short readGroupId; // identify the kind of input data
short readElementId; // identify a particular type
information
short elementLength2; // deal with element length in 2
bytes
G4int elementLength4; // deal with element length in 4
bytes
char * data = new char[DATABUFFSIZE ];
// Read information up to the pixel data
while(true) {
// Reading groups and elements :
readGroupId = 0;
readElementId = 0;
// group ID
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , readGroupId);
// element ID
std:: fread(buffer , 2, 1, dicom);
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GetValue(buffer , readElementId);
// Creating a tag to be identified afterward
G4int tagDictionary = readGroupId *0 x10000 +
readElementId;
// VR or element length
std:: fread(buffer ,2,1,dicom);
GetValue(buffer , elementLength2);
// If value representation (VR) is OB , OW , SQ , UN ,
added OF and UT
//the next length is 32 bits
if(( elementLength2 == 0x424f || // "OB"
elementLength2 == 0x574f || // "OW"
elementLength2 == 0x464f || // "OF"
elementLength2 == 0x5455 || // "UT"
elementLength2 == 0x5153 || // "SQ"
elementLength2 == 0x4e55) && // "UN"
!implicitEndian ) { // explicit VR
std:: fread(buffer , 2, 1, dicom); // Skip 2
reserved bytes
// element length
std:: fread(buffer , 4, 1, dicom);
GetValue(buffer , elementLength4);
// beginning of the pixels
if(tagDictionary == 0x7FE00010) break;
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if(elementLength4 == 0xFFFFFFFF) G4cerr << "Too 
difficult for me!" << G4endl; // VR = SQ with
undefined length
// Reading the information with data
std:: fread(data , elementLength4 ,1,dicom);
} else {
if(! implicitEndian || readGroupId == 2) { //
explicit with VR different than previous
ones
// G4cout << "Reading DICOM files with
Explicit VR"<< G4endl;
// element length (2 bytes)
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , elementLength2);
elementLength4 = elementLength2;
if(tagDictionary == 0x7FE00010) break; //
beginning of the pixels
std:: fread(data , elementLength4 , 1, dicom);
} else { //
Implicit VR
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// G4cout << "Reading DICOM files with
Implicit VR"<< G4endl;
// element length (4 bytes)
if(std:: fseek(dicom , -2, SEEK_CUR) != 0) {
G4cerr << "[CTHandler] fseek failed" <<
G4endl;
exit (-10);}
std:: fread(buffer , 4, 1, dicom);
GetValue(buffer , elementLength4);
// G4cout << std::hex << elementLength4 <<
G4endl;
if(elementLength4 == 0xFFFFFFFF) {
short momreadGroupId;
short momreadElementId;
unsigned int momelementLength4 ; // deal
with element length in 4 bytes
G4cout << "Trying to read nested items!" <<
G4endl; // VR = SQ with undefined length
while(true){
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , momreadGroupId);
std:: fread(buffer , 2, 1, dicom);
GetValue(buffer , momreadElementId);
//G4int momtagDictionary =
momreadGroupId *0 x10000 +
momreadElementId;
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// G4cout << "TAG"<< std::hex <<
momtagDictionary << G4endl;
std:: fread(buffer , 4, 1, dicom);
GetValue(buffer , momelementLength4);
// G4cout << "Length"<< std::hex <<
momelementLength4 << G4endl;
if(momelementLength4 == 0x00000000 ||
momelementLength4 == 0xFFFFFFFF )
break;
std:: fread(buffer , momelementLength4 ,
1, dicom);
}
} else {
if(tagDictionary == 0x7FE00010) break; //
beginning of the pixels
std:: fread(data , elementLength4 , 1, dicom);
}
}
}
// NULL termination
data[elementLength4] = ’\0’;
// analyzing information
GetInformation(tagDictionary , data);
}
// Calculations to crop the image
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DeltaX =( petImagePositionX -ImagePositionX)/
pixelSpacingX;
DeltaY =( petImagePositionY -ImagePositionY)/
pixelSpacingY;
ImagePositionX=ImagePositionX+DeltaX*pixelSpacingX;
ImagePositionY=ImagePositionY+DeltaY*pixelSpacingY;
newrows=int(petrows*petpixelSpacingY/pixelSpacingY)+1;
newcolumns=int(petcolumns *( petpixelSpacingX)/
pixelSpacingX)+1;
G4cout <<"  DeltaX   "<<DeltaX <<"  DeltaY  "<<DeltaY <<"  
newrows  "<<newrows <<"  newcolumns  "<<newcolumns <<G4endl;
// Creating files to store information
std:: ofstream foutG4DCM;
G4String fnameG4DCM = G4String(filename2) + ".g4dcm";
foutG4DCM.open(fnameG4DCM);
G4cout << "### Writing of " << fnameG4DCM << " ### " <<
G4endl;
// foutG4DCM << fMaterialIndices.size() << G4endl;
// --- Write materials
// unsigned int ii = 0;
//std::map <G4float ,G4String >:: const_iterator ite;
//for( ite = fMaterialIndices.begin(); ite !=
fMaterialIndices.end(); ite++, ii++ ){
// foutG4DCM << ii << " " << (*ite).second << G4endl;
//}
// --- Write number of voxels (assume only one voxel in Z)
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foutG4DCM << newrows << " " << newcolumns << G4endl;
foutG4DCM << pixelSpacingX /2<<" "<<pixelSpacingY /2<<" "<<
sliceThickness /2<<G4endl;
// --- Write minimum and maximum extensions
// foutG4DCM << -pixelSpacingX*rows/2 << " " <<
pixelSpacingX*rows/2 << G4endl;
foutG4DCM << ImagePositionX << G4endl;
foutG4DCM << ImagePositionY << G4endl;
foutG4DCM <<ImagePositionZ << G4endl;
// foutG4DCM << sliceLocation -sliceThickness /2. << " " <<
sliceLocation+sliceThickness /2. << G4endl;
// foutG4DCM << compression << G4endl;
ReadData( dicom , filename2 );
StoreData( foutG4DCM );
foutG4DCM.close ();
delete [] buffer;
delete [] data;
return returnvalue;
}
void CTHandler :: GetInformation(G4int & tagDictionary , char *
data) {
if(tagDictionary == 0x00280010 ) { // Number of Rows
GetValue(data , rows);
std:: printf("[0 x00280010] Rows -> %i\n",rows);
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} else if(tagDictionary == 0x00280011 ) { // Number of
columns
GetValue(data , columns);
std:: printf("[0 x00280011] Columns -> %i\n",columns);
} else if(tagDictionary == 0x00280100 ) { // Bits
allocated: This is how much computer memory will be
used to store a pixel sample.
GetValue(data , bitAllocated);
std:: printf("[0 x00280100] Bits allocated -> %i\n",
bitAllocated);
} else if(tagDictionary == 0x00281053) { // Rescale slope
rescaleSlope = atoi(data);
std:: printf("[0 x00281053] Rescale Slope -> %d\n",
rescaleSlope);
} else if(tagDictionary == 0x00281052 ) { // Rescalse
intercept
rescaleIntercept = atoi(data);
std:: printf("[0 x00281052] Rescale Intercept -> %d\n",
rescaleIntercept );
} else if(tagDictionary == 0x00280030 ) { // Pixel Spacing
G4String datas(data);
int iss = datas.find(’\\’);
pixelSpacingX = atof( datas.substr(0,iss).c_str () );
pixelSpacingY = atof( datas.substr(iss+2,datas.length ())
.c_str () );
70
} else if(tagDictionary == 0x00180050 ) { // Slice
Thickness
sliceThickness = atof(data);
std:: printf("[0 x00180050] Slice Thickness (mm) -> %f\n
", sliceThickness);
} else if(tagDictionary == 0x00201041 ) { // Slice
Location
sliceLocation = atof(data);
std:: printf("[0 x00201041] Slice Location -> %f\n",
sliceLocation);
} else if(tagDictionary == 0x00200032 ) { // Image
Position
G4String datas(data);
int iss = datas.find(’\\’);
ImagePositionX=atof( datas.substr(0,iss).c_str() );
G4String datas2=datas.substr(iss+1,datas.length ()).
c_str ();
iss = datas2.find(’\\’);
ImagePositionY = atof( datas2.substr(0,iss).c_str() );
ImagePositionZ=atof(datas2.substr(iss+1,datas.length ()
).c_str ());
std:: printf("[0 x00200032] Image Position (Patient ,mm) 
-> %s\n", data);
} else if(tagDictionary == 0x00020010) { // Endian
if(strcmp(data , "1.2.840.10008.1.2") == 0)
implicitEndian = true;
else if(strncmp(data , "1.2.840.10008.1.2.2", 19) == 0)
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littleEndian = false;
}
}
void CTHandler :: StoreData(std:: ofstream& foutG4DCM)
{
G4int mean;
G4double REdensity;
G4bool overflow = false;
G4int cpt=1;
// ----- Print indices of material
for( G4int ww = 0; ww < newrows; ww++) {
for( G4int xx = 0; xx < newcolumns; xx++) {
mean = newtab[ww][xx];
REdensity = Pixel2REdensity(mean);
foutG4DCM << GetMaterialIndex( REdensity ) << " ";
}
foutG4DCM << G4endl;
}
// ----- Print densities
for( G4int ww = 0; ww < newrows; ww++) {
for( G4int xx = 0; xx < newcolumns; xx++) {
mean = newtab[ww][xx];
REdensity = Pixel2REdensity(mean);
foutG4DCM << REdensity << " ";
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if( xx%8 == 3 ) foutG4DCM << G4endl; // just for nicer
reading
}
}
delete newtab;
}
void CTHandler :: ReadMaterialIndices( std:: ifstream& finData)
{
unsigned int nMate;
G4String mateName;
G4float densityMax;
finData >> nMate;
if( finData.eof() ) return;
G4cout << " ReadMaterialIndices " << nMate << G4endl;
for( unsigned int ii = 0; ii < nMate; ii++ ){
finData >> mateName >> densityMax;
fMaterialIndices[densityMax] = mateName;
G4cout << ii << " ReadMaterialIndices " << mateName << " "
<< densityMax << G4endl;
}
}
unsigned int CTHandler :: GetMaterialIndex( G4float REdensity )
{
std::map <G4float ,G4String >:: reverse_iterator ite;
G4int ii = fMaterialIndices.size();
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for( ite = fMaterialIndices.rbegin (); ite !=
fMaterialIndices.rend(); ite++, ii -- ) {
if( REdensity >= (*ite).first ) {
break;
}
}
//- G4cout << " GetMaterialIndex " << density << " = " <<
ii << G4endl;
return ii;
}
G4int CTHandler :: ReadData(FILE *dicom ,char * filename2)
{
G4int returnvalue = 0;
// READING THE PIXELS :
G4int w = 0;
G4int len = 0;
tab = new G4int*[rows];
for ( G4int i = 0; i < rows; i ++ ) {
tab[i] = new G4int[columns ];
}
newtab = new G4int*[ newrows ];
for ( G4int i = 0; i < newrows; i ++ ) {
newtab[i] = new G4int[newcolumns ];
}
if(bitAllocated == 8) { // Case 8 bits :
std:: printf("@@@ Error! Picture != 16 bits ...\n");
74
std:: printf("@@@ Error! Picture != 16 bits ...\n");
std:: printf("@@@ Error! Picture != 16 bits ...\n");
unsigned char ch = 0;
len = rows*columns;
for(G4int j = 0; j < rows; j++) {
for(G4int i = 0; i < columns; i++) {
w++;
std:: fread( &ch , 1, 1, dicom);
tab[j][i] = ch*rescaleSlope + rescaleIntercept
;
}
}
returnvalue = 1;
} else { // from 12 to 16 bits :
char sbuff [2];
short pixel;
len = rows*columns;
for( G4int j = 0; j < rows; j++) {
for( G4int i = 0; i < columns; i++) {
w++;
std:: fread(sbuff , 2, 1, dicom);
GetValue(sbuff , pixel);
tab[j][i] = pixel*rescaleSlope +
rescaleIntercept;
}
}
}
//crop the image
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for (int j=0;j<newrows;j++){
for (int i=0;i<newcolumns;i++){
newtab[j][i]=tab[j+DeltaY ][i+DeltaX ];
}
}
// write tab to a file
std:: ofstream fouttab;
fouttab.open("tab.dat");
for(int jj=0;jj <rows;jj++){
for(int ii=0;ii <columns;ii++){
fouttab <<tab[jj][ii]<<" ";
}
fouttab <<G4endl;
}
fouttab.close();
std:: ofstream foutnewtab;
foutnewtab.open("newtab.dat");
for(int aa=0;aa <newrows;aa++){
for(int bb=0;bb <newcolumns;bb++){
foutnewtab <<newtab[aa][bb]<<" ";
}
foutnewtab <<G4endl;
}
foutnewtab.close ();
delete tab;
return returnvalue;
}
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G4float CTHandler :: Pixel2REdensity(G4int pixel)
{
G4float REdensity = -1.;
G4int nbrequali = 0;
G4double deltaCT = 0;
G4double deltaDensity = 0;
// print the pixel value
//G4cout <<"pixel value: "<<pixel <<G4endl;
// CT2REDensity.dat contains the calibration curve to convert
CT (Hounsfield) number to relative electron density
std:: ifstream calibration("CT2REDensity.dat");
calibration >> nbrequali;
G4double * valuedensity = new G4double[nbrequali ];
G4double * valueCT = new G4double[nbrequali ];
if(! calibration) {
G4cerr << "@@@ No value to transform pixels in density
!" << G4endl;
exit (1);
} else { // calibration was successfully opened
for(G4int i = 0; i < nbrequali; i++) { // Loop to
store all the pts in CT2REDensity.dat
calibration >> valueCT[i] >> valuedensity[i];
}
}
calibration.close ();
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for(G4int j = 1; j < nbrequali; j++) {
if( pixel >= valueCT[j-1] && pixel < valueCT[j]) {
deltaCT = valueCT[j] - valueCT[j-1];
deltaDensity = valuedensity[j] - valuedensity[j
-1];
// interpolating linearly
REdensity = valuedensity[j] - (( valueCT[j] - pixel
)*deltaDensity/deltaCT );
break;
}
}
if(REdensity < 0.) {
G4cout <<"pixel value: "<<pixel <<G4endl;
std:: printf("@@@ Error density = %f && Pixel = %i (0x%
x) && deltaDensity/deltaCT = %f\n",REdensity ,pixel ,
pixel , deltaDensity/deltaCT);
exit (1);
}
delete [] valuedensity;
delete [] valueCT;
return REdensity;
}
...
From PETCTDetectorConstruction.cc:
...
G4VPhysicalVolume* PETCTDetectorConstruction :: Construct ()
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{
InitialisationOfMaterials ();
// ----- Build world
G4double worldXDimension = 0.5*m;
G4double worldYDimension = 0.5*m;
G4double worldZDimension = 0.5*m;
world_solid = new G4Box( "WorldSolid",
worldXDimension ,
worldYDimension ,
worldZDimension );
world_logic = new G4LogicalVolume( world_solid ,
air ,
"WorldLogical",
0, 0, 0 );
world_phys = new G4PVPlacement( 0,
G4ThreeVector (0,0,0),
"World",
world_logic ,
0,
false ,
0 );
ReadPatientData ();
ConstructPatientContainer ();
ConstructPatient ();
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return world_phys;
}
void PETCTDetectorConstruction :: InitialisationOfMaterials ()
{
// Creating elements :
G4double z, a, density;
G4String name , symbol;
G4Element* elC = new G4Element( name = "Carbon",
symbol = "C",
z = 6.0, a = 12.011 * g/mole
);
G4Element* elH = new G4Element( name = "Hydrogen",
symbol = "H",
z = 1.0, a = 1.008 * g/mole
);
G4Element* elN = new G4Element( name = "Nitrogen",
symbol = "N",
z = 7.0, a = 14.007 * g/mole
);
G4Element* elO = new G4Element( name = "Oxygen",
symbol = "O",
z = 8.0, a = 16.00 * g/mole
);
G4Element* elNa = new G4Element( name = "Sodium",
symbol = "Na",
z= 11.0, a = 22.98977* g/
mole );
G4Element* elS = new G4Element( name = "Sulfur",
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symbol = "S",
z = 16.0,a = 32.065* g/mole
);
G4Element* elCl = new G4Element( name = "Chlorine",
symbol = "P",
z = 17.0, a = 35.453* g/
mole );
G4Element* elK = new G4Element( name = "Potassium",
symbol = "P",
z = 19.0, a = 30.0983* g/
mole );
G4Element* elP = new G4Element( name = "Phosphorus",
symbol = "P",
z = 30.0, a = 30.973976* g/
mole );
G4Element* elFe = new G4Element( name = "Iron",
symbol = "Fe",
z = 26, a = 56.845* g/mole
);
G4Element* elMg = new G4Element( name = "Magnesium",
symbol = "Mg",
z = 12.0, a = 24.3050* g/
mole );
G4Element* elCa = new G4Element( name="Calcium",
symbol = "Ca",
z = 20.0, a = 40.078* g/
mole );
G4Element* elAr = new G4Element( name="Argon",
symbol = "Ar",
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z = 18.0, a = 39.948* g/
mole );
// Creating Materials :
G4int numberofElements;
// Air
air = new G4Material( "air",
1.20*mg/cm3 ,
numberofElements = 3 );
air ->AddElement(elN , 0.755);
air ->AddElement(elO , 0.232);
air ->AddElement(elN , 0.013);
// Soft Tissue
G4Material* softtissue = new G4Material( "softtissue",
density = 1.*g/cm3 ,
numberofElements = 9);
softtissue ->AddElement(elH ,0.1055);
softtissue ->AddElement(elC ,0.2855);
softtissue ->AddElement(elN ,0.0255);
softtissue ->AddElement(elO ,0.5745);
softtissue ->AddElement(elNa ,0.0015);
softtissue ->AddElement(elP ,0.002);
softtissue ->AddElement(elS ,0.0025);
softtissue ->AddElement(elCl ,0.0015);
softtissue ->AddElement(elK ,0.002);
// Muscle
G4Material* muscle = new G4Material( "muscle",
density = 1.05*g/cm3 ,
82
numberofElements = 9 );
muscle ->AddElement(elH ,0.102);
muscle ->AddElement(elC ,0.143);
muscle ->AddElement(elN ,0.034);
muscle ->AddElement(elO ,0.710);
muscle ->AddElement(elNa ,0.001);
muscle ->AddElement(elP ,0.002);
muscle ->AddElement(elS ,0.003);
muscle ->AddElement(elCl ,0.001);
muscle ->AddElement(elK ,0.004);
// Bone
G4Material* bone = new G4Material( "bone",
density = 1.92*g/cm3 ,
numberofElements = 9);
bone ->AddElement(elH ,0.034);
bone ->AddElement(elC ,0.155);
bone ->AddElement(elN ,0.042);
bone ->AddElement(elO ,0.435);
bone ->AddElement(elNa ,0.001);
bone ->AddElement(elMg ,0.002);
bone ->AddElement(elP ,0.103);
bone ->AddElement(elS ,0.003);
bone ->AddElement(elCa ,0.225);
// Blood
G4Material* blood = new G4Material( "blood",
density = 1.06*g/cm3 ,
numberofElements = 10 );
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blood ->AddElement(elH ,0.102);
blood ->AddElement(elC ,0.11);
blood ->AddElement(elN ,0.033);
blood ->AddElement(elO ,0.745);
blood ->AddElement(elNa ,0.001);
blood ->AddElement(elP ,0.001);
blood ->AddElement(elS ,0.002);
blood ->AddElement(elCl ,0.003);
blood ->AddElement(elK ,0.002);
blood ->AddElement(elFe ,0.001);
// ----- Put the materials in a vector
fOriginalMaterials.push_back(air);
fOriginalMaterials.push_back(softtissue);
fOriginalMaterials.push_back(muscle);
fOriginalMaterials.push_back(bone);
fOriginalMaterials.push_back(blood );
// fMaterials.push_back(air);
}
//
-------------------------------------------------------------
void PETCTDetectorConstruction :: ReadPatientData ()
{
std:: ifstream finDF("CT.dat");
G4String fname;
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if(finDF.good() != 1 ) {
G4Exception(" PETCTDetectorConstruction :: ReadPatientData. 
 Problem reading data file: CT.dat");
}
finDF >> fNoFiles;
nVoxelZ = fNoFiles;
for(G4int i = 0; i < fNoFiles; i++ ) {
finDF >> fname;
// --- Read one data file
fname += ".g4dcm";
ReadPatientDataFile(fname);
readflag +=1;
}
finDF.close();
}
//
-------------------------------------------------------------
void PETCTDetectorConstruction :: ReadPatientDataFile(const
G4String& fname)
{
std:: ifstream fin(fname.c_str(), std:: ios_base ::in);
if( !fin.is_open () ) {
G4Exception("PETCTDetectorConstruction :: ReadPatientDataFil
. File not found " + fname );
}
// ----- Define density differences (maximum density
difference to create a new material)
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G4double densityDiff = 0.1;
std::map <G4int ,G4double > fDensityDiffs; // to be able to
use a different densityDiff for each material
for( unsigned int ii = 0; ii < fOriginalMaterials.size(); ii
++ ){
fDensityDiffs[ii] = densityDiff; // currently all materials
with same difference
}
//Read number of voxels
fin >>nVoxelX >>nVoxelY;
//Read size of voxels
fin >>voxelHalfDimX >>voxelHalfDimY >>voxelHalfDimZ;
//Read imageposition
fin >>ImagePositionX >>ImagePositionY >>ImagePositionZ;
if(readflag == fNoFiles -1)
{OffsetX=-( ImagePositionX+ImagePositionX +(nVoxelX -1)*
voxelHalfDimX *2)/2;
OffsetY=-( ImagePositionY+ImagePositionY +(nVoxelY -1)*
voxelHalfDimY *2)/2;
OffsetZ=-( ImagePositionZ+ImagePositionZ -(fNoFiles -1)*
voxelHalfDimZ *2)/2;
G4cout <<OffsetX <<" "<<OffsetY <<" "<<OffsetZ <<G4endl;
}
// ----- Read material indices
G4int nVoxels = nVoxelX*nVoxelY;
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// --- If first slice , initiliaze fMateIDs
if( readflag == 0 ) {
// fMateIDs = new unsigned int[fNoFiles*nVoxels ];
fMateIDs = new size_t[fNoFiles*nVoxels ];
}
unsigned int mateID;
G4int voxelCopyNo = readflag*nVoxels; // number of voxels
from previously read slices
for( G4int ii = 0; ii < nVoxels; ii++, voxelCopyNo ++ ){
fin >> mateID;
fMateIDs[voxelCopyNo] = mateID;
}
// ----- Read material densities and build new materials if
two voxels have same material but its density is in a
different density interval (size of density intervals
defined by densityDiff)
G4double REdensity;
voxelCopyNo = readflag*nVoxels; // number of voxels from
previously read slices
for( G4int ii = 0; ii < nVoxels; ii++, voxelCopyNo ++ ){
fin >> REdensity;
//-- Get material from list of original materials
int mateID = fMateIDs[voxelCopyNo ];
G4Material* mateOrig = fOriginalMaterials[mateID ];
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//-- Get REdensity bin: middle point of the bin in which
the current REdensity is included
float REdensityBin = fDensityDiffs[mateID] * (G4int(
REdensity/fDensityDiffs[mateID ])+0.5);
//-- Build the new material name
G4String newMateName = mateOrig ->GetName ()+"__"+ftoa(
REdensityBin);
//-- Look if a material with this name is already created
(because a previous voxel was already in this REdensity
bin)
unsigned int im;
for( im = 0; im < fMaterials.size(); im++ ){
if( fMaterials[im]->GetName () == newMateName ) {
break;
}
}
//-- If material is already created use index of this
material
if( im != fMaterials.size() ) {
fMateIDs[voxelCopyNo] = im;
//-- else , create the material
} else {
fMaterials.push_back(BuildMaterialWithChangingdensity(
mateOrig , REdensityBin , newMateName ) );
fMateIDs[voxelCopyNo] = fMaterials.size() -1;
}}}
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//
-------------------------------------------------------------
G4Material* PETCTDetectorConstruction ::
BuildMaterialWithChangingdensity( const G4Material*
origMate , float REdensity , G4String newMateName )
{
G4Material* mate;
if(REdensity >=1.1 && REdensity <1.78)
{
// -----For material in Group Bone
// ----Define as a mixture of Bone and Blood
G4int ncomponents;
G4Material* blood=fOriginalMaterials [4];
G4Material* bone=fOriginalMaterials [3];
G4double fractionmassbone =(REdensity -1.050898204)
/(1.781437126 -1.050898204);
G4double fractionmassblood =1- fractionmassbone;
float newdensity=fractionmassbone *1.92+ fractionmassblood
*1.06;
mate=new G4Material(newMateName , newdensity*g/cm3 ,
ncomponents =2);
mate ->AddMaterial(bone , fractionmassbone);
mate ->AddMaterial(blood , fractionmassblood);
}
else{
// ----- For material in Group Air , Soft tissue an Muscle
// ----- Copy the original composition and use a new density
G4int nelem = origMate ->GetNumberOfElements ();
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float newdensity=origMate ->GetDensity ()*REdensity /(origMate
->GetElectronDensity () /(3.34 e23/cm3));
mate = new G4Material( newMateName , newdensity , nelem ,
kStateUndefined , STP_Temperature );
for( G4int ii = 0; ii < nelem; ii++ ){
G4double frac = origMate ->GetFractionVector ()[ii];
G4Element* elem = const_cast <G4Element *>(origMate ->
GetElement(ii));
mate ->AddElement( elem , frac );
}
}
return mate;
}
//
-------------------------------------------------------------
void PETCTDetectorConstruction :: ConstructPatientContainer ()
{
#ifdef G4VERBOSE
G4cout << " nVoxelX " << nVoxelX << " voxelHalfDimX " <<
voxelHalfDimX <<G4endl;
G4cout << " nVoxelY " << nVoxelY << " voxelHalfDimY " <<
voxelHalfDimY <<G4endl;
G4cout << " nVoxelZ " << nVoxelZ << " voxelHalfDimZ " <<
voxelHalfDimZ <<G4endl;
G4cout << " totalPixels " << nVoxelX*nVoxelY*nVoxelZ <<
G4endl;
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#endif
// ----- Define the volume that contains all the voxels
container_solid = new G4Box("PhantomContainer",nVoxelX*
voxelHalfDimX ,nVoxelY*voxelHalfDimY ,nVoxelZ*voxelHalfDimZ
);
container_logic =
new G4LogicalVolume( container_solid ,
fMaterials [0], //the material is not
important , it will be fully
filled by the voxels
"PhantomContainer",
0, 0, 0 );
G4ThreeVector posCentreVoxels (0,0,0);
container_phys =
new G4PVPlacement (0, // rotation
posCentreVoxels ,
container_logic , // The logic volume
"PhantomContainer", // Name
world_logic , // Mother
false , // No op. bool.
1); // Copy number
}
#include "G4SDManager.hh"
#include "G4MultiFunctionalDetector.hh"
#include "G4PSDoseDeposit_RegNav.hh"
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//
-------------------------------------------------------------
void PETCTDetectorConstruction :: SetScorer(G4LogicalVolume*
voxel_logic)
{
G4SDManager* SDman = G4SDManager :: GetSDMpointer ();
// Sensitive Detector Name
G4String concreteSDname = "PatientSD";
// ------------------------
// MultiFunctionalDetector
// ------------------------
//
// Define MultiFunctionalDetector with name.
G4MultiFunctionalDetector* MFDet = new
G4MultiFunctionalDetector(concreteSDname);
SDman ->AddNewDetector( MFDet ); // Register
SD to SDManager
voxel_logic ->SetSensitiveDetector(MFDet);
G4PSDoseDeposit_RegNav* scorer = new
G4PSDoseDeposit_RegNav("DoseDeposit");
MFDet ->RegisterPrimitive(scorer);
}
...
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A.3. Primary Particle Generation and PET Image Sampling
From PETCTPrimaryGeneratorAction.cc
...
PETCTPrimaryGeneratorAction :: PETCTPrimaryGeneratorAction ()
{
//the primary particle is defined with GPS , particle type (e
-), momentum direction (iso), and energy spectrum (hist)
is defined in run.mac
particleGun = new G4GeneralParticleSource ();
}
PETCTPrimaryGeneratorAction ::~ PETCTPrimaryGeneratorAction ()
{
delete particleGun;
}
void PETCTPrimaryGeneratorAction :: GeneratePrimaries(G4Event *
anEvent)
{
G4double ran;//the random number
G4double posX ,posY ,posZ;
G4int vX,vY,vZ;
// Sample Z
//for(int qq=0;qq <50;qq++)// regenerate the random number
number until it is smaller than the probability of vZ
while(true)
{
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ran=CLHEP:: RandFlat :: shoot();// generate a random number in
(0,1)
vZ=CLHEP:: RandFlat :: shoot()*PETHandler :: nFiles;// generate a
random integer vZ between [0,nFiles -1]
if(ran <PETHandler :: PETsum[vZ])
{break ;}
}
// Sample Y
//for(int qq=0;qq <200;qq++)// regenerate the random number
number until it is smaller than the probability of vY
while(true)
{
ran=CLHEP:: RandFlat :: shoot();
vY=CLHEP:: RandFlat :: shoot()*PETHandler ::rows;//vY(integer) is
from [0,rows -1]
if(ran <PETHandler ::sumY[vZ][vY])
{break ;}
}
// Sample X
//for(int qq=0;qq <200;qq++)// regenerate the random number
number until it is smaller than the probability of vX
while(true)
{
ran=CLHEP:: RandFlat :: shoot();
vX=CLHEP:: RandFlat :: shoot()*PETHandler :: columns;//vX is from
[0,columns -1]
if(ran <PETHandler :: image[vZ][vY][vX])
{break ;}
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}
//Get the position: add the offset to relate PET geometry to
CT geometry!
posX=PETHandler :: origX[vZ]+vX*PETHandler :: pixelSpacingX +( CLHEP
:: RandFlat :: shoot() -0.5)*PETHandler :: pixelSpacingX+
PETCTDetectorConstruction :: OffsetX;
posY=PETHandler :: origY[vZ]+vY*PETHandler :: pixelSpacingY +( CLHEP
:: RandFlat :: shoot() -0.5)*PETHandler :: pixelSpacingY+
PETCTDetectorConstruction :: OffsetY;
posZ=PETHandler :: origZ[vZ]+ PETCTDetectorConstruction :: OffsetZ
+( CLHEP:: RandFlat :: shoot() -0.5)*PETHandler :: sliceThickness;
G4ThreeVector pos(posX ,posY ,posZ);
//Set the position
particleGun ->GetCurrentSource ()->GetPosDist ()->
SetCentreCoords(pos);
particleGun ->GeneratePrimaryVertex(anEvent);
}
...
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APPENDIX B
MATLAB COMMANDS
B.1. Reading and Processing Dosimetry Output Files
% Read results from out*.bin files
%The dose is normalized by the total number of particles; unit
: Gy/Bq -s
out=zeros (209 ,209 ,100);
for n=0:9
outname=sprintf(’out_%d.bin’,n);
fid=fopen(outname ,’r’);
for k=1:100
for j=1:209
for i=1:209
num=fread(fid ,1,’float’);
out(j,i,k)=out(j,i,k)+0.1* num;
end
end
end
fclose(fid);
end
%Write 3-D dose distribution in DICOM format
%unit: Gy/Ci-hr
outN=zeros (209 ,209 ,100 ,’uint16 ’);
outN=round(out(j,i,k)*3600*3.7*1 e10);
for i=0:99
%Read CT image headers
filename=sprintf(’IM -0001 -0%03d.dcm’ ,100-i);
header=dicominfo(filename);
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header.SeriesNumber=header.SeriesNumber +1;
header.RescaleIntercept =0;
header.Modality=’Dose’;
CT=dicomread(filename);
CT=CT*0;
%Write dose distribution in the original CT image size
CT (175:383 ,62:270)=outN(:,:,i+1);
newname=sprintf(’Dose -Ocho -0%03d.dcm’ ,100-i);
dicomwrite(CT,newname ,header ,’CreateMode ’,’copy’);
end
B.2. Applying Segmentation and Generating Dose Volume Histogram
%read a segmentation file
fid=fopen(’Bone_and_tumormhdraw ’,’r’);
for k=1:100
for j=1:395
for i=1:512
num=fread(fid ,1,’uint16 ’);
seg(j,i,k)=num;
end
end
end
fclose(fid);
%apply the segmentation mask
R=zeros (395 ,512 ,100);
R(175:383 ,62:270 ,:)=out;
list =0;
for k=1:100
for j=1:395
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for i=1:512
if (seg(j,i,k)==1)
if (( length(list)==1) &&( list ==0) )
list=R(j,i,k);
else
list(length(list)+1)=R(j,i,k);
end
end
end
end
end
%Genarate the dose volume histogram
%ch is the cumulative histogram
n=hist(list ,40);
ch=fliplr(cumsum(fliplr(n)));
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